Compare Summit Therapeutics Inc (SMMT) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Vanguard International High Dividend Yield ETF trades at $101.33. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | VYMI | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $29.32 | $101.60 |
52-Week Low | $13.05 | $79.95 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
VYMI trades at $100.23, down 0.65% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF offers international high dividend yield exposure with over 1,500 stocks and has delivered 10.8% annualized returns over 10 years. Recent institutional buying by D.A. Davidson & CO. increased their position by 265.6% during the latest quarter.
VYMI presents a compelling international diversification opportunity with strong dividend growth potential, though currency fluctuations and global economic conditions pose risks. The ETF's low 0.07% expense ratio and broad diversification across developed and emerging markets provide defensive characteristics in uncertain market environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
